Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
BACKGROUND
The efficacy of systemic antineoplastic therapy on recurrent World Health Organization (WHO) grades II and III meningiomas is unclear.


METHODS
We performed a retrospective multicenter analysis of serial cranial MRI in patients with recurrent WHO II and III meningiomas treated with antineoplastic systemic therapies. Growth rates for tumor volume and diameter, as well as change rates for edema size, were calculated for all lesions.


RESULTS
We identified a total of 34 patients (23 atypical, 11 anaplastic meningiomas) with a total of 57 meningioma lesions who had been treated at 6 European institutions. Systemic therapies included bevacizumab, cytotoxic chemotherapy, somatostatin analogues, and tyrosine kinase inhibitors. Overall, tumor growth rates decreased during systemic therapy by 51% for tumor diameter and 14% for tumor volume growth rates compared with the period before initiation of systemic therapy. The most pronounced decrease in meningioma growth rates during systemic therapy was evident in patients treated with bevacizumab, with a reduction of 80% in diameter and 59% in volume growth. Furthermore, a decrease in size of peritumoral edema after initiation of systemic therapy was exclusively observed in patients treated with bevacizumab (-107%).


CONCLUSIONS
Our data indicate that systemic therapy may inhibit growth of recurrent WHO grades II and III meningiomas to some extent. In our small cohort, bevacizumab had the most pronounced inhibitory effect on tumor growth, as well as some anti-edematous activity. Prospective studies are needed to better define the role of medical therapies in this tumor type.
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Julia
J
Furtner
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Veronika
V
Schöpf
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Katharina
K
Seystahl
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Emilie
E
Le Rhun
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Roberta
R
Rudà
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Ulrich
U
Roelcke
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Susanne
S
Koeppen
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Anna Sophie
AS
Berghoff
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Christine
C
Marosi
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Paul
P
Clement
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Marina
M
Faedi
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Colin
C
Watts
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Wolfgang
W
Wick
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Riccardo
R
Soffietti
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Michael
M
Weller
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (J.F., V.S.); Department of Psychology, University of Graz, Graz, Austria (V.S.); BioTechMed, Graz, Austria (V.S.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (K.S., M.W.); Department of Neuro-oncology, University Hospital, Lille, France (E.L.R.); Breast Cancer Department, Oscar Lambret Center, Lille, France (E.L.R.); PRISM Inserm U1191, Villeneuve D'Ascq, France (E.L.R.); Department of Neuro-Oncology, University of Torino, Torino, Italy (R.R., R.S.); Department of Neurology and Brain Tumor Center, Cantonal Hospital Aarau, Aarau, Switzerland (U.R.); Department of Neurology, University of Essen, Essen, Germany (S.K.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., C.M., M.P.); Department of Oncology, KU Leuven, Leuven, Belgium (P.C.); Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (M.F.); Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, England (C.W.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).
Matthias
M
Preusser
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D001929:Brain Edema / Q000209:etiology*; D001932:Brain Neoplasms / Q000150:complications / Q000473:pathology*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008577:Meningeal Neoplasms / Q000145:classification / Q000150:complications / Q000473:pathology*; D008579:Meningioma / Q000145:classification / Q000150:complications / Q000473:pathology*; D008875:Middle Aged; D012189:Retrospective Studies
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
anaplastic meningioma; anti-angiogenesis; atypical meningioma; bevacizumab; chemotherapy